Kornimate/medical-research-clean huggingface dataset:
investigation of upper extremity functions in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: there are limited studies in the literature evaluating upper extremity functional exercise capacity, muscle functions and daily living activities in rheumatoid arthritis patients. in this context, the aim of this study was to investigate upper extremity exercise capacity, hand grip strength and daily living activities in rheumatoid arthritis patients.

rheumatoid arthritis is an inflammatory autoimmune chronic and systemic disease of unknown etiology. in addition to musculoskeletal involvement, lung involvement can also be observed in patients. lung involvement and accompanying symptoms cause deterioration of physical function, quality of life and functional capacity. in rheumatoid arthritis, dyspnea can be observed during exertion due to disease progression, drug toxicity and respiratory/cardiovascular morbidities. in patients, decreased respiratory muscle strength, respiratory functions, carbon monoxide diffusion capacity and oxygen consumption also cause decreased physical functions. it has been reported that upper extremity exercise capacity and functional performance are reduced in patients with interstitial lung disease. it is known that peripheral muscle strength is an independent determinant of exercise capacity in interstitial lung disease. rheumatoid cachexia, characterized by decreased muscle mass and increased fat mass, is observed in rheumatoid arthritis patients. since the patients' accessory respiratory muscles are also affected, it can negatively affect their daily life activities, especially those that use the upper extremities.

Eligibility criteria:
inclusion criteria: inclusion criteria for patients with rheumatoid arthritis * patients diagnosed with rheumatoid arthritis, * between the ages of 18-75 years, * patients who volunteer to participate in the study will be included in the study. inclusion criteria for the healthy control group * between the ages of 18-75 years, * volunteer to participate in the study will be included in the study. exclusion criteria: exclusion criteria for patients with rheumatoid arthritis * those with serious cardiopulmonary, neurological, neuromuscular, orthopedic and other systemic diseases or other diseases affecting physical functions, * those who have participated in a planned exercise program in the last three months * those with cognitive impairment that will cause difficulty in understanding and following exercise test instructions * patients with contraindications for exercise testing or exercise training according to the american sports medicine association will not be included in the study. exclusion criteria for the healthy control group * those with any diagnosed chronic or systemic disease, * those who smoke 10 packs x years or more, * those who have pneumonia or any acute infection, * healthy individuals with any psychiatric disorder will not be included in the study.

Keywords: exercise capacity upper extremity hand-grip strength
brain connectivity in neurodevelopmental disorders in response to treatment

Conditions: Autism Spectrum Disorders; Psychosis; Fragile X Syndrome

Summary: the purpose of the proposed research is to study the potential changes in biomarkers of patients with neurodevelopmental disorders in response to treatment in clinical trials or in private psychiatry practice utilizing non-invasive psychophysiological measurements. the investigators plan to obtain psychophysical measurements throughout several periods of treatment.

this study will employ a non-invasive custom-built four-point vertical displacement stimulator. this is used to deliver sinusoidal vibrations at very low amplitudes (0-400 microns) to the tips of the fingers. the forearm of the subject rests on the stimulator, the finger tips are vibrated, and the subject answers questions prompted by a computer monitor about their perception of the stimuli. research staff may explain questions and prompts in a way that may be better understood by the subjects if the subjects experience any difficulty. this device will be used to obtain objective psychophysical measurements as subjects undergo treatment. the investigators hope that this study will eventually assist in the long term goal of studying ways to develop diagnostic methods, based on changes in cortical information processing capabilities that occur with neurodevelopmental disorders. this would enable clinicians to more objectively determine prognosis and the best course of intervention for their patients. this study will consent up to 60 subjects who are have initiated or changed pharmacologic treatment as either a participant in a clinical trial or as a private patient of one of the study doctors. subjects who are a participant in another clinical trial may be one an active medication or a non-active medication(placebo). subjects will have 7 visits in this study (w0 prior to initiating new treatment, and 4,8, 26 52,78 and 104 weeks after starting the the new treatment. the latter visits may occur either while the individual is taking the medication or after the individual has stopped treatment (in order to assess persistence of treatment-related changes).

Eligibility criteria:
inclusion criteria: * subjects who are eligible to participate in a clinical trial conducted by dr. sikich or individuals who have initiated/changed pharmacologic treatment (as private patient of a study physician) * diagnosis of autism spectrum disorder (asd), psychotic spectrum disorder (psd), or fragile x syndrome. * ages 3-45 inclusive exclusion criteria: • non-english speaking subject or parent/guardian
patient-reported outcome measures in lower extremity rehabilitation program prom_r: impact on health care

Conditions: Lower Extremity Problem; Rehabilitation; Knee Injuries

Summary: different musculoskeletal conditions affect people all over the world and were considered by the who to be the leading cause of disability in 4 out of 6 regions in 2017, with an increase in the associated burden and impact on society expected in the coming years. the knee is a complex joint, vulnerable to various types of injury. the most common are ligament, meniscus and cartilage injuries of different etiologies. after surgery, as a result of the reflex inhibition of motor neurons and immobilization, there is rapid atrophy and weakness in the different associated muscles, affecting proprioception, muscle strength and extension, clearly compromising health-related quality of life. through partnership and collaboration between health institutions and academia, the rehabilitation program will take place on an outpatient basis in a supervised manner, allowing its effectiveness to be assessed using patient-reported outcome measures. these instruments are a rapidly developing topic and it is essential to understand whether the patient-reported outcome measures used are sufficient to measure the results perceived by patients with lower limb pathology who take part in rehabilitation programs. the different patient-reported outcome measures will be applied before and after the program.

the study design is a clinical trial with longitudinal assessment, with a convenience sample. participants who meet the inclusion criteria are invited to take part and sign an informed consent form. all participants' data is encrypted and stored with password protection, and will be deleted once the results of the study have been published. the experimental group followed the program for 4 weeks with a treatment frequency of 5 sessions per week, performed and supervised by the same specialist physiotherapist at every session. for the statistical analysis of the data in this study, we used the statistical package for social sciences (spss®) 29 software.

Eligibility criteria:
inclusion criteria: * patients with knee and ankle pathology, undergoing surgery; * that they are going to start a rehabilitation program in two rehabilitation clinics in coastal and inland regions of portugal; * aged between 18 and 80; * have signed an informed consent form. exclusion criteria: * unconsolidated fractures; * previous surgeries in the ipsilateral knee; * partial or total amputation in upper or lower limbs; * permanent or temporary dysfunctions of the central or peripheral nerve system.

Keywords: quality of life patient-reported outcome measures
reliability of rehabilitative ultrasound for the quadriceps muscle and sarcopenia in poststroke patients

Conditions: Sarcopenia; Stroke, Complication; Quadriceps Muscle Atrophy; Hemiplegia; Ultrasonography; Hand Strength

Summary: the purpose of the study is search the interrater and intrarater reliability of the quadriceps muscle using rehabilitative ultrasound imaging and search for an association between sarcopenia and quadriceps muscle in poststroke patients.

poststroke patients often suffer from muscle atrophy in quadriceps muscle. quadriceps muscle is essential for independent standing or ambulation after stroke. quadriceps muscle consists of four different muscles: rectus femoris, vastus intermedius, vastus lateralis and medialis. the present study search for reliability for rectus femoris and vastus intermedius muscle thickness and cross-sectional area using rehabilitative ultrasound imagining. longitudinal and transverse ultrasound imagining of the muscle thickness will be performed on both rectus femoris and vastus intermedius muscles for both extremities. the procedures will be repeated by two experts at two separate times (7-10 days). for sarcopenia measurement grip strength and dexa measurements of the patients will be calculated. totally 68 patients will be included in the study.

Eligibility criteria:
inclusion criteria: * poststroke patients (\>6 months) exclusion criteria: * \< 6 months after stroke * multiple stroke

Keywords: sarcopenia stroke quadriceps muscle atrophy hemiplegia ultrasonography hand strength
analgesic efficacy of sacral neuromodulation for pelvic cancer pain: a preliminary report

Conditions: Chronic Pain

Summary: in this trial, we will test the analgesic efficacy of sacral neuromodulation for patients with pelvic cancer, complaining of chronic pelvic pain in comparison to medical treatment.


Eligibility criteria:
inclusion criteria: * age, 18-70 * pain localized to the pelvic and perineal region * the pain is due to pelvic cancer or chronic pelvic pain after pelvic surgery for cancer * the intensity of pain assessed by vas (visual analogue pain scale) \> 7 * importantly, the included participants should gain \> 50% reduction of their pain in response to sacral roots block, s2,3 and 4 with bupivacaine 0.5%, 2 ml for each root exclusion criteria: * coagulopathy * infection at site of maneuver * abnormal psychological behavior that interfere with integrity of obtained data
breast cancer recurrence risk counseling

Conditions: Breast Cancer Female

Summary: the number of breast cancer survivors is growing. women with a personal history of breast cancer worry about their risk of getting cancer again. the current study will develop counseling about breast cancer recurrence risk and will also get an estimate of the preliminary impact of this counseling. the goal is to enable women to make better decisions about their treatment.


Eligibility criteria:
inclusion criteria: * women who (1) have a personal history of a single stage 0-2 breast cancer, (2) were recently diagnosed within the past 6 months, and (3) are treated at a participating breast oncology clinic. exclusion criteria: * women who are unable to read/write in english.
treatment of humerus fractures by a multiloc nail, through a minimally invasive procedure.

Conditions: Humeral Fractures

Summary: proximal humerus fractures are more common in older people. they can be caused by a minor trauma on an osteoporotic bone. non- or little-displaced proximal humerus fractures are treated orthopedically. when the displacement is more important, the choice of the treatment is crucial and the algorithm of treatment is in permanent evolution. the technology and design of the implants and the operative techniques of osteosynthesis and arthroplasty have evolved. patients live longer, they lead a more active life and their expectations have changed. the goals of the treatment should be an increase in shoulder function and a decrease in treatment failure. this study analyzes the results of the treatment by intramedullary osteosynthesis using a multiloc nail from synthes between 2012 and june 2017. the study will compare the functional results obtained after fixation by a multiloc nail, a philos plate or arthroplasty.the functionality of the shoulder and the quality of life will be evaluated according to the type of treatment.


Eligibility criteria:
inclusion criteria: all patients being treated for a proximal humerus fracture within the chu brugmann hospital between 2012 and 2017. exclusion criteria: none
a study to determine the maximum tolerated dose of elesclomol sodium given with a fixed dose of docetaxel and prednisone in patients with metastatic prostate cancer

Conditions: Prostate Cancer

Summary: this aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. this study will also characterize the pharmacokinetics of elesclomol and docetaxel.

this aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant prednisone. this study will also characterize the pharmacokinetics of elesclomol and docetaxel.

Eligibility criteria:
inclusion criteria * confirmed metastatic prostate cancer * no more than one prior chemotherapy on which the disease progressed * ecog performance status of less than or equal to 2 * adequate bone marrow, renal and hepatic functions as defined in the protocol * neuropathy less than or equal to 2 * reliable venous access for frequent study drug infusions exclusion criteria * significant cardiovascular disease * known active brain metastases * subjects that have received treatment for other malignancies with in the past 5 years * other clinically significant uncontrolled conditions

Keywords: prostate cancer metastatic castration refractory elesclomol sodium docetaxel prednisone
the relationship between clotting factor viii and bleeding adverse reactions in patients under the therapies of thrombolysis, anticoagulation and anti-platelet

Conditions: Bleeding; Ischemic Stroke

Summary: the purpose of this study is to determine whether plasma factor viii levels are related to the treatment of bleeding in ischemic stroke（is）.

clear cerebral infarction patients during hospitalization, treatment process, discharge and hemorrhage occurs, the stages f viii level change and its correlation with bleeding adverse reactions. analysis f viii whether belong to hemorrhage occurs independent risk factors of adverse drug reactions,as well as the feasibility of predicting bleeding occurred adverse reaction index.

Eligibility criteria:
inclusion criteria: * guidelines prepared by the diagnostic criteria(according to the diagnostic criteria of the fourth national stroke conference prepared,have been more than one times skull ct and/or mri)was confirmed for ischemic stroke,and requires the use of antithrombotic therapy(including thrombolysis, anticoagulation, antiplatelet) patients * willing and able to comply with the study protocol and visits planned exclusion criteria: * at the same time the presence of other active malignancy. * there is known brain metastases or leptomeningeal metastases * systemic active infection ( ie infection leads to body temperature ≥38 ℃) * the last 4 weeks there is a need drainage ascites, pleural effusion or pericardial fluid . * clinically significant obstruction , pulmonary fibrosis , kidney failure , liver failure and other diseases. * uncontrolled diabetes. * severe / unstable angina, new york heart association (nyha) class iii or iv symptoms of congestive heart failure * there is other reason (not the antithrombotic drugs) caused by bleeding. * the presence of an autoimmune disease or a history of organ transplant patients require immunosuppressive therapy * psychiatric presence may increase the risks associated with study participation or study drug , or may interfere with the interpretation of study results * pregnant and lactating women * bleeding disorders may exist on admission * the researchers added that the study is not appropriate to the circumstances

Keywords: plasma factor viii levels ischemic stroke antithrombotic therapy bleeding
safety and efficacy of a 6% hydroxyethyl starch (hes) solution versus an electrolyte solution in trauma patients

Conditions: Hypovolemia Due to Acute Blood Loss

Summary: the aim of the study is to investigate the safety of a 6% hydroxyethyl starch (hes) solution (volulyte 6%) versus an electrolyte solution (ionolyte) in trauma patients.


Eligibility criteria:
inclusion: * male or female adult patients ≥18 years of age. women of child bearing potential must test negative on standard pregnancy test (urine or serum) (as soon as possible during emergency care) * patients with blunt or penetrating trauma suffering from estimated blood loss of ≥ 500 ml * initial surgery deemed necessary within 24 hrs after trauma * deferred signed written informed consent form or as locally required * no signs of intracranial or cerebral hemorrhage * administration of less than 15 ml/kg body weight colloid between trauma injury and hospital admission. exclusion: * hypersensitivity to the active substances or to any of the other excipients of the investigational products * body weight ≥ 140 kg * patients expected to die within 24h after traumatic injury * sepsis * burns * renal impairment (akin stage ≥ 1 or chronic) or acute and/or chronic renal replacement therapy * critically ill patients (typically admitted to the intensive care unit) * hyperhydration * pulmonary edema * dehydration * hyperkalemia * severe hypernatremia * severe hyperchloremia * severely impaired hepatic function * congestive heart failure * severe coagulopathy * organ transplant patients * metabolic alkalosis * simultaneous participation in another interventional clinical trial (drugs or medical devices studies)

Keywords: hydroxyethyl starch hes hes 130
a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of jnj-38431055, sitagliptin, and co-administration of jnj-38431055 and sitagliptin

Conditions: Diabetes Mellitus, Type 2

Summary: this study will assess the safety, tolerability, pharmacokinetics (explores what the body does to the drug), and pharmacodynamics (explores what a drug does to the body) of single doses of jnj-38431055, sitagliptin, and co-administration of jnj-38431055 and sitagliptin in healthy overweight or obese adult male volunteers.

this is a double-blind (neither physician or volunteer knows the name of the assigned study drug), placebo controlled (substance containing no medication), study in healthy, overweight or obese adult male volunteers. for each volunteer, the study consists of a screening phase (up to 30 days), a treatment phase during which volunteers will receive 4 study treatments in a randomized (study sequence assigned by chance) sequence (28 days), and a follow-up phase (10 days). during the treatment phase there will be at least 7 days between each of the 4 treatments. the four treatments will be jnj-38431055, sitagliptin, jnj-38431055 and sitagliptin, and placebo. the following safety evaluations will be taken throughout the study: electrocardiogram (an ecg is a painless procedure that gives a picture of the electrical activity of the heart), blood pressure, heart rate, and blood samples for laboratory tests. the primary outcome will be the effect of jnj-38431055 and sitagliptin on glucagon like peptide-1 (glp-1) levels. study drug will be administered as single oral doses separated by at least 7 days. the four treatments will be jnj-38431055, sitagliptin, jnj-38431055 and sitagliptin, and placebo.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) between 27.0 and 38.0 kg/m2 (inclusive) * healthy on the basis of physical examination including medical history, vital signs, 12-lead ecg, and all other screening lab tests * men must agree to use a double barrier method of birth control (e.g., condom for them and use of spermicide with diaphragm, hormonal contraceptives or intrauterine devices by female partner) during the study and for three months following the last dose of study medication, and to not donate sperm during the study and for 3 months after receiving the last dose of study medication exclusion criteria: * history of, or currently active, illness or medical condition or disorder that the investigator considers to be clinically significant * smoker or tobacco user within the past 6 months * history of recent major surgery (within 6 months of study start) * positive test for alcohol and/or drugs of abuse * psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study requirements * any condition that, in the opinion of the investigator, would compromise the well being of the volunteer or the study or prevent the volunteer from meeting or performing study requirements

Keywords: type 2 diabetes mellitus